|Mr. Joseph Jimenez Jr.||Chief Exec. Officer||N/A||N/A||58|
|Mr. Harry Kirsch||Chief Financial Officer||2.79M||N/A||53|
|Dr. Felix R. Ehrat Ph.D.||Group Gen. Counsel||N/A||N/A||61|
|Mr. Steven Baert||Head of HR||2.2M||N/A||44|
|Mr. Andr?? Wyss||Global Head of Corp. Responsibility||2.44M||N/A||51|
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segments also franchises ophthalmology, neuroscience, immunology and dermatology, respiratory, cardio-metabolic, and other medicines, as well as cell and gene therapies. The Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The Alcon segment offers eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses for use in surgical procedures to treat cataracts, vitreoretinal conditions, glaucoma, and refractive errors; and contact lenses and lens care products. The company has collaboration and licensing agreements with Xencor for the development of bispecific antibodies for treating cancer; and Surface Oncology to access four pre-clinical programs in immuno-oncology. It also has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and Caribou Biosciences for the development of drug discovery tools. In addition, the company has a clinical research collaboration with Bristol-Myers Squibb Company to investigate Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist as a treatment option for metastatic colorectal cancer. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Novartis AG’s ISS Governance QualityScore as of January 1, 2018 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 9; Compensation: 7.